All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.
Institute of Genomics & Integrative Biology, Delhi, India.
Biomark Med. 2024 Mar;18(5):191-202. doi: 10.2217/bmm-2023-0476. Epub 2024 Mar 8.
Coronary artery disease (CAD) has a high mortality rate. Despite various therapeutic targets, non-responsiveness to drugs remains a prevalent issue. Pharmacogenomics assesses the way an individual's genetic attributes affect their likely response to drug therapy. Single-nucleotide polymorphisms play a crucial role in determining these outcomes. This review offers an overview of single-nucleotide polymorphisms investigated in clinical studies and their associations with drug response/nonresponse in the treatment of CAD. A total of 104 studies of whole sets of chromosomes and several genes were explored. A total of 161 polymorphisms exhibited associations with drug response/nonresponse in CAD across diverse ethnic populations. This pool can serve as a pharmacogenomic biomarker for predicting response to drug therapy in patients with CAD.
冠心病（CAD）死亡率高。尽管有各种治疗靶点，但药物无应答仍是一个普遍存在的问题。药物基因组学评估个体的遗传特征如何影响他们对药物治疗的可能反应。单核苷酸多态性在确定这些结果方面起着至关重要的作用。这篇综述概述了在临床研究中研究的单核苷酸多态性及其与 CAD 药物反应/无反应的关系。总共探讨了整套染色体和几个基因的 104 项研究。共有 161 个多态性与不同种族人群的 CAD 药物反应/无反应相关。这一组可以作为预测 CAD 患者药物治疗反应的药物基因组生物标志物。
